메릴랜드의 삼중음성 유방암 임상 시험
삼중음성 유방암 관련 연구 18개가 메릴랜드 내 여러 지역에서 참여자를 모집하고 있습니다.
메릴랜드의 도시
공식 연구 텍스트(영어)
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구
18세 ~ 120세 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT07619534A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
- MedStar Southern Maryland Hospital Center ( Site 0100), Clinton
- 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06841354Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Holy Cross Hospital ( Site 0069), Silver Spring
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06393374A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06966700Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- United Theranostics, Glen Burnie
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07020117Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT03606967Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT05633654PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
피험자 모집 중2상
18세 이상 · 여성 · 2026. 9. 3. 업데이트됨 · NCT06245889A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
- National Institutes of Health Clinical Center, Bethesda
피험자 모집 중
18세 ~ 120세 · 모든 성별 · 2026. 8. 21. 업데이트됨 · NCT07067138A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 1035, Baltimore
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 4. 업데이트됨 · NCT05579366Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT07327489Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- National Institute of Health Clinical Center, Bethesda
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT05660083Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- United Theranostics, Glen Burnie
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 3. 업데이트됨 · NCT07311993A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 11. 4. 업데이트됨 · NCT05902988A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- University of Maryland Medical Center (UMMC), Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 6. 19. 업데이트됨 · NCT06568692First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2022. 11. 28. 업데이트됨 · NCT05627960ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.